Publication date: Apr 05, 2022 Immunocore Holdings LimitedPRESS RELEASEEuropean Commission Approves KIMMTRAK (tebentafusp) for the treatment of unresectable or metastatic uveal melanomaKIMMTRAK is the first and only treatment approved in ... Read more

Publication date: Mar 19, 2022 One a trial for patients who had been previously treated with something else for uveal melanoma, and then, really, the pivotal trial was a ... Read more

Publication date: Feb 25, 2022 The randomized pivotal trial evaluated overall survival (OS) of KIMMTRAK compared to investigators choice (either pembrolizumab, ipilimumab, or dacarbazine) in patients with previously untreated mUM. ... Read more